🌟 Join IMBdx at Medtec Japan 2024! 🌟 Discover the future of liquid biopsy technology at Test Kit EXPO booth no. 2411 from April 17th to 19th, 2024. IMBdx, a leading liquid biopsy company, is excited to showcase our latest innovations in ctDNA-based precision diagnostics solutions across the full continuum of cancer care. Don't miss this opportunity to connect with us and explore the forefront of liquid biopsy. See you there! # IMBdx #LiquidBiopsy # MedtecJapan2024 #Innovation #CancerCare #Profiling #MRD #MCED #TokyoBigSight
소개
혈액 기반으로 종양을 초기에 진단하고, 모니터링 하기 위해 설립된 국내 최초의 기업으로써 글로벌 선두기업들과 경쟁할 수 있는 국내 유일의 기술력을 갖춘 기업입니다.
- 웹사이트
-
http://www.imbdx.com/eng
아이엠비디엑스 외부 링크
- 업계
- 생명공학 연구
- 회사 규모
- 직원 51-200명
- 본사
- Seoul
- 유형
- 비상장기업
- 설립
- 2018
위치
아이엠비디엑스 직원
업데이트
-
🌟 Join IMBdx Virtually at BIO-Europe SPRING 2024! 🌟 Experience the future of liquid biopsy technology from the comfort of your home at the BIO-Europe SPRING conference 2024. IMBdx, a pioneering liquid biopsy company, is thrilled to participate virtually in this esteemed event. Explore our latest innovations in ctDNA-based precision diagnostics solutions across the full continuum of cancer care. Connect with us online to delve into the forefront of oncology diagnostics. Don't miss out on this opportunity to engage with industry leaders and discover how IMBdx is shaping the future of cancer care. See you at BIO-Europe SPRING 2024! # IMBdx #LiquidBiopsy # BIO-EuropeSPRING2024 #VirtualConference #Innovation #CancerDetection #Profiling #MRD #MCED
-
-
아이엠비디엑스님이 퍼감
🎄🌟 Celebrating Achievements & Wishing Joy! 🎉✨ As the year draws to a close, we at IMBdx reflect on a year of remarkable accomplishments in liquid biopsy innovation: 🌍 AlphaLiquid®100 prescribed by 33 major hospitals domestically & expanded globally to 20 regions. 🔬 Blood-based HRR Testing for mCRPC in partnership with AstraZeneca. 🚀 Successful launches of CancerDetect in Asia & CancerFind in Korea. 🏆 CAP Accreditation secured. 🌟 KOSDAQ Technology Evaluation (A, A) achieved. 📚 Eight groundbreaking publications in leading journals. Thanks to our valued partners & and collaborators for their unwavering support! May your holiday season be filled with warmth, joy, and cherished moments. Here's to continued success and innovation in the New Year! Merry Christmas and a Prosperous New Year from the IMBdx team! 🎁🎉 #christmas2023 #newyear2024 #liquidbiopsy #precisionmedicine #profiling #mrd #cancerscreening #cancerawareness #earlydetection #targetedtherapy #personalizedmedicine
-
-
🎄🌟 Celebrating Achievements & Wishing Joy! 🎉✨ As the year draws to a close, we at IMBdx reflect on a year of remarkable accomplishments in liquid biopsy innovation: 🌍 AlphaLiquid®100 prescribed by 33 major hospitals domestically & expanded globally to 20 regions. 🔬 Blood-based HRR Testing for mCRPC in partnership with AstraZeneca. 🚀 Successful launches of CancerDetect in Asia & CancerFind in Korea. 🏆 CAP Accreditation secured. 🌟 KOSDAQ Technology Evaluation (A, A) achieved. 📚 Eight groundbreaking publications in leading journals. Thanks to our valued partners & and collaborators for their unwavering support! May your holiday season be filled with warmth, joy, and cherished moments. Here's to continued success and innovation in the New Year! Merry Christmas and a Prosperous New Year from the IMBdx team! 🎁🎉 #christmas2023 #newyear2024 #liquidbiopsy #precisionmedicine #profiling #mrd #cancerscreening #cancerawareness #earlydetection #targetedtherapy #personalizedmedicine
-